Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology
August 24 2015 - 9:00PM
Business Wire
Burning Rock and Illumina, Inc. (NASDAQ: ILMN)
today announced they have entered into an agreement whereby Burning
Rock will develop advanced clinical applications for molecular
diagnostics in oncology based on Illumina’s next-generation
sequencing (NGS) technology. The collaboration highlights the
ever-increasing importance of genomics to improve healthcare
in China.
In recent years, NGS has evolved rapidly and is widely regarded
as an essential technology for enabling precision medicine. The
collaboration between Burning
Rock and Illumina will focus on providing the most
advanced and integrated sequencing solutions to the clinical market
by combining Illumina sequencing technology
with Burning Rock’s advanced clinical application development
capabilities. In particular, the two companies will work together
to develop a user-friendly, oncology molecular diagnostic kit for
the Chinese market. As part of the agreement, Burning
Rock will provide its nucleic acid extraction, library
preparation, and data analysis software,
while Illumina will provide NGS instrument components and
related reagents.
“We have been working to promote the clinical application of
genomic technology in China. Oncology molecular
diagnosis based on NGS, including non-invasive testing, is
being applied in the clinic and we hope to promote it as a standard
practice in hospitals. As the leader in oncology molecular
diagnosis, Burning Rock is now very pleased to partner
with Illumina, the global leader in sequencing and array-based
technologies. Cooperation between our two companies will provide
additional high-quality molecular diagnostic solutions in the
clinical field of oncology,” said Yusheng
Han, the Founder and Chief Executive Officer of Burning
Rock.
“Illumina is very excited to collaborate with Burning
Rock to increase access to oncology diagnosis solutions in
China,” said Dr. Rick Klausner, Senior Vice President and
Chief Medical Officer of Illumina. “We are committed to
partnering with Chinese companies who share our vision of improving
human health by unlocking the power of the genome.”
About Burning Rock
Burning Rock is headquartered in Guangzhou, China, and
is a diagnostics company committed to the field of molecular
testing to improve oncology patients’ individualized treatment
guidance. It offers research and commercialized clinical laboratory
services mainly through bioinformatics on NGS platforms. Burning
Rock has a state-of-art molecular and pathological examination
platform, containing NGS, qPCR, IHC, FISH and digital pathology. In
oncology molecular testing, Burning Rock has developed a
series of testing solutions. To learn more,
visit www.brbiotech.com.
About Illumina
Illumina is improving human health by unlocking the power
of the genome. Our focus on innovation has established us as the
global leader in DNA sequencing and array-based technologies,
serving customers in the research, clinical and applied markets.
Our products are used for applications in the life sciences,
oncology, reproductive health, agriculture and other emerging
segments. To learn more, visit www.illumina.com and
follow @illumina.
Forward-Looking Statements
This release may contain forward-looking statements that involve
risks and uncertainties. Important factors that could cause actual
results to differ materially from those in any forward-looking
statements are detailed in Illumina’s filings with the Securities
and Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date
of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150824005884/en/
Burning RockMedia:Bin Wei, +86-20-34037871, ext.
858Bin.wei@brbiotech.comorIllumina, Inc.Investors:Rebecca
Chambers, 858-255-5243rchambers@illumina.comorMedia:Jennifer
Temple, 858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024